Basic Information
| Drug ID | DDPD00246 |
|
| Drug Name | Ziprasidone | |
| Molecular Weight | 412.936 | |
| Molecular Formula | C21H21ClN4OS | |
| CAS Number | 146939-27-7 | |
| SMILES | ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1 | |
| External Links | ||
| DRUGBANK | DB00246 | |
| PubChem Compound | 60854 | |
| PDR | 2532 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 3.8 | - | 3.8 | - | DRUGBANK |
| Melting Point | 276.0 | ℃ | >276 | ℃ | https://www.trc-canada.com/product-detail/?CatNum=Z485000 |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Absorption | 100.0 | % | 100.0 | % | DRUGBANK | ||
| Bioavailability | 60.0 | % | 60.0 | % | DRUGBANK | Bioavailability | 100.0 | % | 100.0 | % | PO, oral; food; | food ↑ ; | DRUGBANK | Bioavailability | 59.0 | % | 59.0 | % | PO, oral; | The Pharmacological Basis of Therapeutics | Bioavailability | 100.0 | % | 100.0 | % | IM,intramuscular injection; | The Pharmacological Basis of Therapeutics |
| C Max | 68.0 | ng/ml | 68±20 | ng/ml | PO, oral; | The Pharmacological Basis of Therapeutics | C Max | 156.0 | ng/ml | 156.0 | ng/ml | The Pharmacological Basis of Therapeutics |
| T Max | 4.0 | h | 4±1 | h | PO, oral; | The Pharmacological Basis of Therapeutics | T Max | 0.70 | h | 0.7 | h | The Pharmacological Basis of Therapeutics |
| Clearance | 0.45 | L/h/kg | 7.5 | ml/min/kg | Average clearance; | DRUGBANK | Clearance | 0.70 | L/h/kg | 11.7 | ml/min/kg | The Pharmacological Basis of Therapeutics | Clearance | 0.31 | L/h/kg | 5.1 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 1.5 | L/kg | 1.5 | L/kg | Apparent volume of distribution; | DRUGBANK | Volume of Distribution | 2.3 | L/kg | 2.3 | L/kg | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.0 | L/kg | 1 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 6.5 | h | 6-7 | h | DRUGBANK | Half-life | 2.9 | h | 2.9 | h | Elderly ↑ ;food ↓ ; | The Pharmacological Basis of Therapeutics | Half-life | 3.1 | h | 3.1 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Eliminate Route | 1.0 | % | <1 | % | Urinary excretion; PO, oral; Unchanged drug; | DRUGBANK | Eliminate Route | 4.0 | % | <4 | % | Faeces excretion; PO, oral; Unchanged drug; | DRUGBANK | Eliminate Route | 1.0 | % | <1 | % | Urinary excretion; PO, oral; Unchanged drug; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 99.0 | % | >99 | % | plasma proteins; | DRUGBANK | Protein Binding | 99.9 | % | 99.9±0.08 | % | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 40.0 | mg/day | 40 | mg/day | PO, oral | Geodon | (ziprasidone hydrochloride); (ziprasidone mesylate) | PDR |
| Max dose for children | 10.0 | mg/dose | 10 | mg/dose | IM,intramuscular injection | Geodon | (ziprasidone hydrochloride); (ziprasidone mesylate) | PDR |
| Max dose for children | 40.0 | mg/day | 40 | mg/day | PO, oral | Geodon | (ziprasidone hydrochloride); (ziprasidone mesylate) | PDR |
| Max dose for adolescents | 40.0 | mg/day | 40 | mg/day | PO, oral | Geodon | (ziprasidone hydrochloride); (ziprasidone mesylate) | PDR |
| Max dose for adolescents | 20.0 | mg/dose | 20 | mg/dose | IM,intramuscular injection | Geodon | (ziprasidone hydrochloride); (ziprasidone mesylate) | PDR |
| Max dose for adolescents | 40.0 | mg/day | 40 | mg/day | PO, oral | Geodon | (ziprasidone hydrochloride); (ziprasidone mesylate) | PDR |
| Max dose for adolescents | 10.0 | mg/dose | 10 | mg/dose | IM,intramuscular injection | Geodon | (ziprasidone hydrochloride); (ziprasidone mesylate) | PDR |
| Max dose for adults | 160.0 | mg/day | 160 | mg/day | PO, oral | Geodon | (ziprasidone hydrochloride); (ziprasidone mesylate) | PDR |
| Max dose for adults | 40.0 | mg/day | 40 | mg/day | IM,intramuscular injection | Geodon | (ziprasidone hydrochloride); (ziprasidone mesylate) | PDR |
| Max dose for geriatric | 160.0 | mg/day | 160 | mg/day | PO, oral | Geodon | (ziprasidone hydrochloride); (ziprasidone mesylate) | PDR |
| Max dose for geriatric | 40.0 | mg/day | 40 | mg/day | IM,intramuscular injection | Geodon | (ziprasidone hydrochloride); (ziprasidone mesylate) | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1